loss_pro BOCX - 500 Beiträge pro Seite

[morchel]

du hast irgendwo mal BOCX erwähnt!

Was hältst du von der Situation?

morchel

[js200]

11/05/2003 (13:11 ET) VOLUME(-): BOCX Volume 51% > 20-adsv, Stock -12.35% - Knobias
11/04/2003 (11:16 ET) VOLUME(+): BOCX Volume 28% > 20-adsv, Stock +24.14% - Knobias
11/03/2003 (10:33 ET) VOLUME(+): BOCX Volume 21% > 20-adsv, Stock +21.74% - Knobias
11/03/2003 (09:45 ET) Stocks Opening Significantly Higher/Lower Than Close - Knobias
11/03/2003 (08:53 ET) SmallCap Digest Covers BOCX - Knobias

JS200

[js200]

SmallCap Digest Covers BOCX

Monday , November 03, 2003 08:53 ET

A recent SmallCap Digest alert talks about BIOCUREX INC (OTCBB: BOCX).

BOCX has developed proprietary tissue and blood tests to detect the RECAF marker in virtually all cancers.

On 10/31/2003, BOCX closed at $0.23000, *** BIOCUREX INC (OTCBB: BOCX)

The SmallCap Digest is owned by TGR, LLC.

According to the SmallCap Digest disclaimer, TGR Group LLC was compensated $25,000 and 1,000,000 newly issued restricted shares by Biocurex for coverage of the company.

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


11/05/2003 (13:11 ET) VOLUME(-): BOCX Volume 51% > 20-adsv, Stock -12.35% - Knobias



11/04/2003 (11:16 ET) VOLUME(+): BOCX Volume 28% > 20-adsv, Stock +24.14% - Knobias



11/03/2003 (10:33 ET) VOLUME(+): BOCX Volume 21% > 20-adsv, Stock +21.74% - Knobias



11/03/2003 (09:45 ET) Stocks Opening Significantly Higher/Lower Than Close - Knobias



11/03/2003 (08:53 ET) SmallCap Digest Covers BOCX - Knobias



10/27/2003 (09:51 ET) VOLUME(-): BOCX Volume 115% > 20-adsv, Stock -15.00% - Knobias



10/24/2003 (12:47 ET) HotStockChat.com Covers BOCX, DWLD, EFTI and VRAL - Knobias



10/24/2003 (09:48 ET) Stocks Opening Significantly Higher/Lower Than Close - Knobias



10/24/2003 (09:46 ET) VOLUME(+): BOCX Volume 93% > 20-adsv, Stock +35.48% - Knobias



10/24/2003 (08:26 ET) BOCX Announces Study of RECAF(TM) Cancer Detection - Knobias



10/24/2003 (08:04 ET) Hopital Europeen Georges Pompidou Begins Clinical Evaluation of BioCurex Cancer Detection Kits - Business Wire



10/23/2003 (14:49 ET) Breast Cancer Awareness and BioCurex Inc. - PrimeZone Media Network, Inc.



10/23/2003 (08:02 ET) Hopital Europeen Georges Pompidou Begins Clinical Evaluation of BioCurex Cancer Detection Kits - PrimeZone Media Network, Inc.



10/22/2003 (17:12 ET) Breast Cancer Awareness and BioCurex Inc. - PrimeZone Media Network, Inc.



10/22/2003 (14:11 ET) VOLUME(-): BOCX Volume 65% > 20-adsv, Stock -5.88% - Knobias



10/20/2003 (11:01 ET) VOLUME(+): BOCX Volume 25% > 20-adsv, Stock +2.94% - Knobias



10/16/2003 (11:46 ET) VOLUME(+): BOCX Volume 76% > 20-adsv, Stock +20.00% - Knobias


JS200

[loss_pro]

mann, js muß ja echt schon WO-süchtig sein...

@ morchel

ebenso wie fast alles, was hier gerade in WO mit pop-up beworben wird, hatte die im frühjahr schon ihren hype. im aktuellen gesamtmarkt mit +50% in den letzten paar tagen hingegen, zumind. subjektiv , bisher ein underperformer. scheinen aber wieder gut anzufangen zu laufen. tut ja aber praktisch alles like it´s 1999...
tradingtechnisch ein kauf sobald der preis sich anschickt wieder zu steigen... ähhh, ich seh gerade, daß wäre u.U. 1 stunde vor schluß schon der fall gewesen.

fundamental scheint ja gering bewertet, story hört sich zumind. für nicht-ärzte(wie mich) gut an, guter news flow. was will man mehr?

ps: wie bei vielen pharma OTCs, bei denen man nicht weiß neues wundermittel oder snake oil salesman, angeblich böse shorties
naja, S8 + bezahlter push... aber am ende is ja egal warum es steigt

wenn doch nur nicht immer alles gleichzeitig laufen würde

[morchel]

Von der Story finde ich GMXX auch interessant!

Hatte vor kurzem mall ein Gespräch mit einem Can-Schweizer, der hällt große Stücke auf den Laden!

Wie meist liegts an der Aktionärsstruktur!

morchel

[loss_pro]

von GMXX halte ich eigentlich nix. shorties haben normalerweise richtig gute gründe für ihr handeln. die sagen ja nicht einfach: ach, da shorten wir mal nen paar stück und machen dann einen auf kostolany...

[morchel]

Will GMXX nicht verteidigen aber ich habe gehört das LOM hinter den Shortbeständen steckt!
Ein kanadischer Broker, die meist für alle short bei BB Firmen bezichtigt werden hat strenge Auflagen und die SEC schaut ihnen in letzter zeit besonders genau auf die Finger! Will ein Klient oder der Broker selbst short verkaufen, so muß er sich die Aktien irgendwo ausleihen können!
Findet man keine, so geht man zu LOM. Durch ihre Offshore Präsenz können die beinahe machen was sie wollen. Die sagen immer das sie welche haben und betreiben ganz ungeniert "naked shorting"!

LOM hat schon viele eigentlich nette Geschichten zerstört! so hab ich es jedenfalls von einem "Kenner der Szene" gehört!


Bei GMXX sind angeblich noch ein paar 100k short!

morchel

[umbertoni]

Kann mich nur an die naked short selling story bei Genemax erinnern. Das ist ne Verbrecheraktie..da wäre ich ganz ganz vorsichtig!!!

[UH1d]

China Grants BioCurex`s RECAF Patent: Largest Population Country In The World Approves Technology
Wednesday November 12, 8:05 am ET


RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--Nov. 12, 2003--BioCurex Inc. (OTCBB:BOCX - News) is pleased to announce that a patent for its proprietary RECAF(TM) technology for cancer diagnosis has been approved and granted in the People`s Republic of China. The patent covers the technologies used in the Company`s Histo-RECAF(TM) and Cryo-RECAF(TM) kits as well as (Serum-RECAF(TM)) a cancer diagnostic blood test. Further, the patent protects other cancer diagnostic applications such as leukemia to be developed in a near future.
Dr. Ricardo Moro, BioCurex`s CEO stated: "China`s healthcare market is one of the most dynamic and rapidly changing in the world and that creates abundant opportunities for foreign companies. The Chinese healthcare market is generally underestimated. For example, China is now estimated to have more CT instruments than the United States. The healthcare industry in China has posted double-digit (16 percent) average growth, annually, for a decade. China`s transition into a free market economy, coupled with drastic reforms in the health sector and intellectual property protection have increased business opportunities for small and medium-sized foreign pharmaceutical, biotechnology and medical companies." In-vivo RECAF(TM) applications, such as cancer imaging, therapy and vaccination remain pending under a continuation in part of the original application. Similar patents have already been issued in the United States, Australia and Russia and they are pending in most European countries, Canada and Japan.

According to a report from Genesis Technology Group, China`s drug sales reached US$6.8 billion in 2002, and are expected to rise to US$14 billion in 2005 and to US$24 billion in 2010. The pharma revenue in China is about US$20 billion, of which approximately 48%, 30% and 22% come from the sales of joint venture, domestic and imported products, respectively. The size of the industry will equal that of the United States by 2020.

The Globoscan 2000 cancer database states that there are about 1.9 million new cases and about 1.4 million deaths annually from cancer in China. With a population of approximately 1.3 billion, China is a vast market for cancer therapies. Cancer became the main cause of death in China in 1996.

China is the fastest growing pharmaceutical market in the world and currently ranks as the ninth largest pharmaceutical market with nearly US$7 billion in sales in 2001. China`s changing healthcare environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services.

About BioCurex:

BioCurex Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Histo-RECAF(TM) kits provide proof of concept for the RECAF technology. Detailed information about BioCurex may be obtained from its Web site.

Note:

The company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the company`s actual results could differ materially from expected results.



--------------------------------------------------------------------------------

[ayurveda]

Berlin BXI EUR 0,340 0,770 + 0,430 + 126,47 12.163 20.100 05. Apr 15:02

Was passiert da?

[ayurveda]

Die geht total ab
OTCBB BOCX USD 0,539 1,22 + 0,681 + 126,35 2,85 Mio. 2.857.507 05. Apr 15:37

[Henrys]

1,41
Nicht schlecht
Das soll mal PBDY nachmachen
cu Henrys

[Henrys]

so jetzt bei 1,80

cu Henrys

[Spekulatius_28]

was denkt ihr wie weit das noch geht?
gibt es ein KZ?
speku

[Spekulatius_28]

USA RT 2,14
Dann müsste in Berlin ja noch was gehen oder was meint ihr?
Speku

[BFCist]

BioCurex Blood Test Detects 90% of Leading Cancer Killer

2004-04-05 08:30 ET - News Release

RANCHO SANTA MARGARITA, Calif. -- (Business Wire) -- April 5, 2004

BioCurex Inc. (OTCBB:BOCX) announces results for lung
cancer detection using its proprietary Serum-RECAF(TM) blood test. The
results confirm 90% sensitivity with 95% specificity*.
The findings further substantiate the use of RECAF(TM) as a
universal cancer marker with a potential market size of $2 billion per
year for all cancers.
The study included 32 lung cancer patients and 103 normal donors
with statistical verification.
Dr. Moro commented: "Lung cancer is a terrible disease. It kills
more people than any other type of cancer and it kills in a terrible
way, by asphyxiation. It is gut wrenching to realize that even thought
this is a preventable disease, the number of new cases and deaths
keeps increasing each year. It is well established that early
diagnosis results in better prognosis and that is why it was so
important to develop a sensitive lung cancer test that catches 90% of
cases with only 5% of false positives. Moreover, there is no other
blood test that can detect lung cancer at the present time. The
ultimate benefit to society could be enormous."
These results are consistent with those obtained for other types
of cancer and strengthen the concept of using Serum-RECAF(TM) as a
valid test for screening the general populations for cancer. Since
lung cancer, as well as many other cancers, is difficult to detect,
the overall value of the RECAF technology in human and market terms is
significant.
Dr. Moro further stated, "It is not well understood by the general
public, that we have very few methods available to tell if a person
has a cancer. In fact, for most cancers, there are no existing
specific tests. This is why RECAF is such a valuable technology. Even
if we could only detect one type of cancer, we would have a
significant discovery, but the studies demonstrate that we obtain
continued excellent results in many differing types of cancers and at
very high detection values. We are very excited about our potential as
a biotech company."

[Marchella]

Würde die Hälfte jetzt verkaufen,den Rest laufen lassen!

[Spekulatius_28]

bin leider erst zu 1.58 rein. gibt es denn kein vorläufiges kursziel (ca. bis freitag)
kenne mich leider noch nicht so aus, aber man lernt ja gern dazu
Speku

[js200]

Last Trade: 2.380 Change: 1.841 (+341.558%)
Previous Close: 0.539 Volume: 25,788,400
Bid: 2.320 Ask: 2.320
Today`s Open: 1.290 # of Trades: 11,893

--------------------------------------------------------------------------------

Day High: 2.550 Day Low: 1.100
52 Week High: 0.539 52 week Low: 0.003
Market Cap: 28.49M Avg Daily Vol: 508,363
EPS: N/A PE Ratio: N/A
Dividend: N/A Yield: N/A

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


04/05/2004 (11:14 ET) Reported on by Emerging Stock Report - Knobias



04/05/2004 (10:43 ET) BOCX: Reported on by Hototc.com - Knobias



04/05/2004 (09:52 ET) BOCX: New 52-Wk High @ $1.300 up 141.19% - Knobias



04/05/2004 (09:24 ET) BOCX: Updates Results of Serum-RECAF Blood Test - Knobias



04/05/2004 (08:30 ET) BioCurex Blood Test Detects 90% of Leading Cancer Killer - Business Wire



04/05/2004 (00:49 ET) StockGate: Naked ShortSelling `End` Sees Big Price Variations in a Dozen `Shorted` Stocks - Investrend - Financial Wire



04/04/2004 (12:02 ET) USOTC: Traders Nation lands on front cover of Pennycents Magazine - M2 Communications



04/04/2004 (12:01 ET) Emerging Stock Report: Emerging Stock Report "daily stock pick" this morning is: Biocurex Inc (OTCBB:BOCX) - M2 Communications



04/04/2004 (10:49 ET) Emerging Stock Report: Emerging Stock Report "daily stock pick" this morning is: Biocurex Inc (OTCBB:BOCX) - M2 Communications



04/04/2004 (10:13 ET) Financial Relations Inc: Traders Nation lands on front cover of Pennycents Magazine - M2 Communications



04/02/2004 (17:03 ET) BOCX: Announces 2004 Initiatives for its RECAF Technology - Knobias



04/02/2004 (16:56 ET) BioCurex: Aggressively Moves Ahead with 2004 Strategic Plan - Business Wire



04/02/2004 (10:05 ET) BOCX: New 52-Wk High @ $0.440 up 7.32% - Knobias



04/01/2004 (04:08 ET) StockGrid.com: Stock Watch List for Monday, April 5, 2004: BOCX - M2 Communications



03/31/2004 (06:20 ET) BOCX: Filed New Form NT 10-K - Edgar


JS200

[morchel]

Sakrament!



morchel

[Spekulatius_28]

hoffentlich gehts morgen so weiter

[ayurveda]

Da ist Luft bis 6-8 Dollar auf Jahresende sogar bis 10 Dollar, wenn Ihr mich fragt.

Few Reasons to Own BOCX:

1.. BOCX has patented and proprietary technology that is leading the way in early cancer detection.
2.. BOCX is currently developing and commercializing cancer diagnostic products based upon their breakthrough RECAFTM cancer marker technology.
3.. A vaccine based on BOCX`s proprietary RECAFTM technology that would protect against most types of cancer has a $2B market potential in U.S. alone.
4.. Radioisotope imaging of RECAFTM positive cancer cells can be obtained with standard hospital equipment. Projected as a $1B U.S. market share for BOCX.
5.. $ 2 Billion Dollar market targeted for BOCX`s single serum test for the diagnosis of numerous types of cancer. To be launched under the name Serum-RECAFTM.
6.. $3 Billion Dollar market share is seen as realistic as BOCX joins the Antibody Therapy arena with very favorable results from preliminary studies based on BOCX`s RECAFTM technology.
7.. BOCX targets growing market for minimizing or eliminating side effects of cancer chemotherapy, utilizing its RECAFTM antibodies for drug and radioisotope delivery.
8.. BOCX is seen as a prime-licensing candidate based on the multitude of clinical uses of BOCX`s proprietary RECAF TMtechnology.
9.. BOCX has assembled a team of renowned individual scientists and experts under the direction of Dr. Phillip Gold, the most eminent investigator in the cancer marker field.
10.. Investigators at BOCX have demonstrated that leukemia can be diagnosed and monitored utilizing BOCX`s RECAFTM staining technology. By cleansing patients` bone marrow of cancer cells, need for bone marrow transplants might be eliminated.
11.. BOCX`s Histo-RECAFTM, a special cancer detection kit for tissues, has been cleared for sale by the FDA for U.S. markets, with an early projected market potential of $200 million.
12.. Histo-RECAFTM HAS BEEN CLEARED BY THE FDA FOR SALE IN THE USA.

ABOUT BOCX
BOCX is biotechnology company dedicated to the development of innovative healthcare solutions for the new millennium. The first of these groundbreaking new technologies is in the field of cancer diagnosis, tumor imaging, and treatment. The technology identifies a widespread cancer biomarker known as RECAFTM, which enables the potential for detection of the vast majority of malignant cancers from blood tests, tissue biopsies or other specimen types.

Put simply, RECAFTM is the only biomarker known to be present in most types of cancer cells and BOCX`s patented technology is the only means to detect it. What`s more, RECAFTM technology distinguishes cancer cells from normal cells and malignant tumors from benign tumors.

Research indicates RECAFTM is present in practically 100% of breast cancers and in approximately 90% of cancers overall. The technology may also be applied to pinpoint the exact location of a cancer in the body using imaging technology. It is anticipated that RECAFTM will replace certain other biomarkers that may only detect one type of cancer or are not sensitive or specific to a particular malignancy. Its widespread nature indicates that RECAFTM technology may be applied to cancers for which there are no other effective markers - particularly breast and lung cancers, which together represent one third of all cancers.

In addition to the USA, BOCX has patents pending for RECAFTM in more than 20 countries and has already received patents in Australia and Russia.

Investment Opportunity
BACKGROUND

In North America, there are over 8 million cancer patients and approximately 1 million new cases are reported each year. Over 1/3 of the population will develop cancer at some point during their life and over one-half million people die from cancer each year. The new incidences of cancer along with the maintenance of persons living with cancer will continue to increase the demand for cancer products. The present world market for cancer therapeutics is approximately US$12 billion per year. The National Cancer Institute estimates overall annual costs for cancer in the U.S. at US$104 billion with US$35 billion in direct medical costs and the remainder in productivity and mortality-related costs. Approximately 1/2 of the direct costs are related to the treatment of breast, lung and prostate cancers.

TECHNOLOGY

A novel widespread cancer marker named RECAFTM. Cancer markers` are molecules that appear on cancer cells but not on normal cells and finding new ones is one of the most important goals in cancer research (only half a dozen have been found in the past 40 years). PSA (prostate cancer) and CEA (colorectal cancer) are well known cancer markers. They can by used to detect (diagnose) and then specifically target cancer cells (therapy) -- offering the potential to provide treatment of cancer by delivering antibodies, drugs and radiation to the targeted cancerous cells.

PRODUCTS

Histo-RECAFTM HAS BEEN CLEARED BY THE FDA FOR SALE IN THE USA.

Its sister product, Cryo RECAFTM - for use for diagnosis on frozen sections while the patient is under anesthesia - is fully developed and awaiting further testing prior to FDA submission. BOCX is actively working on the serum test, which will be launched under the name Serum- RECAFTM.

MARKET POTENTIAL IN THE USA ALONE

Pathology $200M
Blood tests $2B
Imaging $1B
Antibody therapy $3B
RECAF Vaccine $2B


Valuation
How many times have you seen issues explode but you couldn`t get your hands on them? We are alerting you to a special company with a unique product that is set to explode on Monday -- this is your chance to get in! BOCX is a high-growth microcap issue and should be purchased only by stock traders and investors that set aside a portion of their portfolio for this type of investment. BOCX is an exciting company with an exciting new technology -- go get it now!

[loss_pro]

PKTX läuft übrigens im BOCX schlepptau, is noch nicht ganz so stark gestiegen.

[MRASTA]

Coole Geschichte.

Nur die Meldung, die alle zum Aufbruch bewegt hat, mich auch, gebe ich zu, war bereits im Mai 2003 aktuell ??????

http://biz.yahoo.com/pz/030528/40856.html


Und warum haben Sie bis dato nix an den Mann gebracht ? Seit 2001 keinen Partner in Canada gefunden oder wie muss man dass verstehen ?


In August of 2001, the Company received approval for its Histo-RECAF(TM) kit from Canada`s Health Products and Food Branch division under License No. 31198.

In January 2003, the Company was advised by the F.D.A. that its Histo-RECAF(TM) test kit was classified as a Class I medical device. This classification allows the Company to sell its Histo-RECAF(TM) kits in the United States.

As of October 30, 2003 the Company has not sold any Histo-RECAF(TM) test kits.

Due to the costs involved in manufacturing and marketing the Company plans to license the Histo-RECAF(TM) technology to third parties.


mrasta

[Muckibaby]

Im August von 2001, empfing die Firma Zustimmung für seinen Histo-RECAF(TM) Installationssatz von der Canada`s Gesundheit Produkt-und Nahrungsmittelniederlassung Abteilung unter Lizenz Nr. 31198. Im Januar 2003, wurde die Firma durch das F.D.A. beraten, daß sein Histo-RECAF(TM) Testinstallationssatz als Kategorie I medizinische Vorrichtung eingestuft wurde. Diese Klassifikation erlaubt der Firma, seine Histo-RECAF(TM) Installationssätze in den Vereinigten Staaten zu verkaufen. Ab Oktober 30, hat 2003 die Firma keine Histo-RECAF(TM) Testinstallationssätze verkauft. Wegen der Kosten bezog in Herstellung und in Marketing die Firmapläne mit ein, um die Histo-RECAF(TM) Technologie zu den dritten Beteiligten zu genehmigen.

[MRASTA]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[TraderAlex]

was ist den am freitag neues passiert?

[js200]

BOCX: Reported on by SmallCap Digest

Monday , April 12, 2004 10:08 ET

A recent SmallCap Digest alert noted the following about BioCurex Inc (OTCBB: BOCX).

"The shares of BioCurex have recently been on a tear. Trading in the stock idled at a sleepy 20 cents a share just two weeks ago."

"Inexplicably, the stock charged up to 50 cents in two trading days, and then went on a wild run which saw an unprecedented $3.90 high as millions of shares changed hands."

"On Thursday, after the market closed, the SEC suspended trading in the shares of BioCurex until April 22nd pending a review of the company’s claims concerning its technology."

BOCX has a current price of $1.92000 per share.

The SmallCap Digest newsletter is owned by TGR, LLC.

According to the SmallCap Digest disclaimer, TGR Group LLC was compensated $25,000 and 1,000,000 newly issued restricted shares by Biocurex for coverage of the company.

[MRASTA]

SEC Believes BioCurex News Too Good to Be True


Monday , April 12, 2004 07:51 ET
Apr 12, 2004 (financialwire.net via COMTEX) -- (FinancialWire) Shares of BioCurex, Inc. (OTCBB: BOCX) have been suspended from trading by the U.S. Securities and Exchange Commission until April 22.

The SEC is questioning the accuracy of statements in press releases and emails regarding the effectiveness of the company`s primary product and its purported approval by the U.S. Food and Drug Administration.

The company`s stock had skyrocketed last week from pennies to $3.90 before closing April 8 at $1.92, on announcements that it had developed a blood test that "detects 90% of a leading cancer killer."

The SEC is challenging a press release that stated "the company developed and reported on a tissue test" and "received FDA recognition for its ability to detect cancer cells."

[na_fets]

brutal, wie schnell es vorbei sein kann!

[MRASTA]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[brasileiro58]

biocurex veröffentlichung:
http://cbs.marketwatch.com/tools/quotes/newsarticle.asp?site…


RICHMOND, British Columbia, Apr 19, 2004 (BUSINESS WIRE) -- BioCurex Inc. (Pink Sheets:BOCX) is pleased to provide a clarification of the FDA classification of its Histo-RECAF(TM) product.

In May 2001, BioCurex submitted an application to the FDA regarding its Histo-RECAF(TM) kit. The submission included data, pictures from stained tissue sections and reports from pathologists who had evaluated the test. It also included the user manual, which was revised and corrected according to the instructions and helpful suggestions from the FDA officer.

The Food and Drug Administration (FDA) subsequently classified BioCurex`s Histo-RECAF(TM) as a Class I device under Regulation Number 864.1850(i). Item (b) reads:

-- (b) Classification. Class I (general controls). These devices
are exempt from the premarket notification procedures in
subpart E of part 807 of this chapter subject to the
limitations in Sec. 864.9. These devices are also exempt from
the current good manufacturing practice regulations in part
820 of this chapter, with the exception of Sec. 820.180, with
respect to general requirements concerning records, and Sec.
820.198, with respect to complaint files.


The FDA has not "approved" the Histo-RECAF product for the diagnosis of cancer. Instead, the FDA has classified Histo-RECAF(TM) as a Class I device (lower cost and time frame) which allows BioCurex to sell the product for use as specified in its manual as follows:

-- Intended Use

-- Histo-RECAF(TM) is a qualitative ligand-binding histochemical
test kit for use as an adjunct to standard light microscopy
staining methods for detection of alphafetoprotein binding on
formalin-fixed, paraffin-embedded tissue sections as an aid in
the identification of breast cancer in breast and axillary
node tissues. Diaminobenzidine is the chromogen used in the
test kit.


Furthermore, the Company directs the pathologist in the Limitations section of that manual as follows:

-- 5) The clinical interpretation of any positive staining or its
absence must be evaluated within the context of clinical
presentation, morphology and other histopathological criteria.
The clinical interpretation of any staining, or its absence
must be complemented by morphological studies and proper
controls as well as other diagnostic tests. Staining is to be
performed in a certified licensed laboratory under the
supervision of a pathologist who is responsible for reviewing
the stained slides and assuring the adequacy of positive and
negative controls.


The pathologist who examines a tissue biopsy under the microscope typically looks for specific abnormalities associated with cancer. These can include invasion of adjacent areas and shape and size of cells. To visualize these features, the cells must be colored with a stain; for example Hematoxylyn & Eosin or the Papanicolau stain used for PAP smears. Histo-RECAF can also assist the pathologist by staining malignant cells. The FDA has placed Histo-RECAF(TM) within the classification name: "STAIN, PAPANICOLAU(ii)", the stain used in PAP smears used for detection of cancer. The Papanicolau stain is not "approved" as a device for "cancer diagnosis" either, but its role as a stain in the diagnosis of cervical cancer is undeniable.

Histo-RECAF(TM), as a Class I device, is intended to assist the pathologist who will still rely on multiple tools and morphological criteria for reaching a final diagnosis.

For more information about the FDA approving process, visit: http://www.fda.gov/cdrh/devadvice/3122.html

[stawu]

schon etwas älter, vom 16. 4.2004

http://www.biospace.com/ccis/news_story.cfm?StoryID=15790720…

BioCurex Inc. (BOCX): Preliminary Results On RECAF From George Pompidou Hospital -Paris- Described As "Very Positive"


RICHMOND, British Columbia--(BUSINESS WIRE)--April 16, 2004--BioCurex, Inc. (Pink Sheets:BOCX) announced today that Protokinetix announced preliminary results from a study carried out by the George Pompidou Hospital in France which was designed to validate the Company`s Histo-RECAF(TM) version 2.0. This version uses a high affinity anti-RECAF antibody which improves the contrast between cancer cells and the surrounding non-malignant tissue.

The study was commissioned by Protokinetix Inc., which was granted a license by BioCurex to commercialize therapeutic anti-RECAF antibodies modified according to Protokinetix`s Super-Antibody proprietary technology and the Perigene (Compiegne, France) catalytic antibody technology.

Dr. Jean-Marie Dupuis, a scientist involved with the Pompidou validation study, described the results obtained with BioCurex kits as "very positive" and stated that "the labeling of the malignant cells is strong and clear with a nice delineation between malignant and normal cells."

Dr. Ricardo Moro, CEO of BioCurex, stated: "We are very pleased with these very preliminary results, which validate our claims at a time in which our technology is under scrutiny.

"The findings are very significant because the study is being carried out by an extremely reputable institution. The results are also important to us because the study uses our new anti-RECAF antibody which works significantly better than the former reagent in the kit.

"We are looking forward to the final conclusions of this study. We expect that the Pompidou analysis will continue to confirm the positive results we have obtained in our own research facilities. Moreover, we are excited about the potential of combining the Super-Antibody and the Catalytic-Antibody technologies with our own RECAF(TM) technology.

"BioCurex has pending patents for a number of cancer therapy applications using RECAF(TM). These applications cover conjugates between anti-RECAF antibodies with a variety of drugs, radio-isotopes and a cancer vaccine."

This second version of Histo-RECAF being tested by the Pompidou group has not been yet submitted to the FDA

stawu

[Spekulatius_28]

Wan denkt ihr wird sie wieder in berlin gehandelt? in USA ist schon wieder, oder wie kann ich sie bei comdirekt verkaufen. Wäre über jeden hilfe dankbar!
bei comdirekt wird ab jetzt gesagt, das die nicht in deutschland gehandelt wird!
Danke im voraus

[leuchturm]

wie schauts aus leute soll man die aktie jetzt kaufen oder nicht!!!!

[Spekulatius_28]

wäre nett, wenn jemand die frage beantworten könnte!
wan handel in berlin?

[gauner1]

zu 36 und 38

ich kann leider deine frage nicht beantworten. ich hätte das so gerne getan

[gauner1]

ich bin aber der meinung, dass es unmöglich ist, dass das papier nicht mehr in berlin gehandelt wird. man kann ein papier nicht einfach aus dem handel nehmen. vielleicht braucht berlin etwas technische vorbereitung, nachdem das papier ca. 2 wochen nicht gehandelt wurde. hoffentlich geht es am montag los. es kann doch gar nicht möglich sein, dass das ganze geld weg ist. das ist unvorstellbar.
vielleicht kann der börsenaufsicht in berlin eine auskunft geben. die nummer habe ich nicht, da ich bis sonntag früh im betrieb bin. zu hause habe ich. werde dir am sonntag reinstellen.

gruss gauner

[Spekulatius_28]

Hallo,
habe heute mit denen von comdirect telefoniert und die sagten, das berlin den handel vorerst komplett eingestellt hat!

die wollen meine stücke aber jezt so umstellen, das ich sie in USA verkaufen kann. kann aber vielleicht bis mittwoch dauern, leider!


konnte ja keine ahnen, das der handel aussetzt.
viel glück
Speku

[MRASTA]

@all

Das liegt vielleicht daran, dass Die durch die SEC Regelung erstmal in die Pinksheets abgeschoben wurden. D.h. wenn ein OTC-BB Wert für mehr als 4 Tage ausgesetzt ist, geht es automatisch ab in den Pinksheet Bereich.



After 4 days without trading activity, the NASD automatically moves OTCBB stocks to the Pink Sheets.

To restart trading, whether it is in the Pink Sheets or on the OTCBB, a dealer/broker needs to file with the NASD, a Form 2-11 to demonstrate compliance with Rule 15c2-11 of the Securities Act of 1933.



BioCurex wishes to thank all of its shareholders for their patience and assures them that we are all doing our best to have trading in our shares resume as soon as possible. We are confident that once the pending issues are resolved, the focus will return to the relevance of our RECAF technology.


mrasta

[gauner1]

spekulatus

das freut mich fuer dich. wirklich wollte ich das dir das selbe vorschlagen, dass du versuchst, dass die papiere in usa verkauft werden. natuerlich kannst du durch comdirekt auch in usa handeln, aber nur wenn du papiere in usa kaufst. man kann nicht ein papier hier kaufen und dort verkaufen oder in usa kaufen und hier verkaufen.

aber in diesem fall kann der comdirekt das tun. die frage ist aber jetzt, wann du verkaufst. wenn du im gewinn bist, dann wuerde ich verkaufen. wenn du in verlust bist, soll man erst nachforschen, warum der kurs von 1,97 bis 1,27 gesunken ist. der kurs war sogar am freitag sogar viel niedriger. wenn das gewinnmitnahmen gewesen sind, dann ist es zu ueberlegen, ob du verkaufst oder noch wartest.

und ich werde mir ueberlegen, ob ich kaufe oder nicht. ich muss also den grund wissen, warum das papier aus dem handel genommen wurde und warum der kurs gesunken ist. ? hast du vielleicht eine erklaerung ?

uebrigens ich bin mit 2,10 eingestiegen und bei 1,60 verkauft. das waren genau 2000 euro verlust plus die gebuehren. ich wuerde gerne mein geld wieder rausholen.

gruss gauner

[Spekulatius_28]

@gauner

Die Aktie ist ausgesetzt worden, weil die meldung http://home.businesswire.com/portal/site/home/index.jsp?epi-… angezweifelt wurde.

zur überaschung ist nun gestern eine neue meldung http://home.businesswire.com/portal/site/home/index.jsp?epi-… rausgekommen, die gutes hoffen lässt. ehrlich gesagt, habe ich mir vorgenommen im plus zu verkaufen. nur lasse ich comdirect jetzt das schon einrichten, damit ih jederzeit handeln kann, falls es einen neuen hype geben sollte.


ich denke, dass wir dort gutes hoffen können.
Speku

[MRASTA]

+32%

BOCX: Presents Raw Data from RECAF Blood Test
Monday , April 26, 2004 02:59 ET

BioCurex Inc. (BOCX.PK) presents the raw data, analysis and conclusions pertaining to a study released on April 5th 2004 on lung cancer detection using our RECAF blood test. The internal study indicated that Serum-RECAF(TM) can discriminate cancers from normal serum samples with 90% sensitivity and 95% specificity.

[gauner1]

spakulatius

ich habe die meldung von gestern nicht gelesen. freut mich fuer euch, dass es heute gute steigerung gegeben hat. das volumen war auch gut. ich glaube an weiterem anstieg. ich kann leider nicht einsteigen, weil ich wo anders voll investiert bin.

wuensche euch alles gute. ich werde das papier weiter beobachten. eins ist sicher. es ist kein risiko dabei, wenn man vom tagesschwankungen absieht. das papier wird sicher mit volatieln schueben steigen

gruss gauner

[gauner1]

kurs 2 dollar. das freut mich fuer euch. das muss fuer euch sehr sehr stressig gewesen sein, als der kurs ausgesetzt und in berlin nicht mehr gehandelt wurde. vor allen dingen war bis 1 dollar gesunken.

[gauner1]

2,05

[Preisfuchs]

auch ich bin nach gutem verkauf wieder investiert

[Kannestahl]

mich würde an dieser Stelle schon mal interessieren wie es jetzt weitergeht, wann Berlin den Handel wieder aufnimmt usw., kennt sich da jemand gut aus?

[Spekulatius_28]

@Kannestahl

wie schon geschriebn, hatte ich bei meinem broker angerufen, und die sagten, das in berlin komplett ausgesetzt wurde. deswegen stellen die meine stück jetzt um, das ich in usa verkaufen kann.

ich hatte leider erst bei 2,35 Euro gekauft!
da hilft nur hoffen, aber auch in den US Board wird die aktie auf jeden fall auf langzeit sehr gut bewertet.

krebsforschung wird immer aktuell sein. und wenn dann noch gute ergebnisse kommen, kann es nur besser werden.
Speku

[Spekulatius_28]

Es gibt neues

BioCurex Announces Validation of its Cancer Detection System by Research Centers And Hospitals In Japan.
RICHMOND, British Columbia, May 4, 2004 -- BioCurex Inc. (BOCX.PK) announced today the results of an independent evaluation of the company’s Histo-RECAFTM based cancer detection system in Japan.

The work, which was started last year, involved Dr. Kazuhita Taketa, MD, Head of the Clinical Trial Center and Emeritus Professor, Okayama University and Dr. SoTsuboi, Shigei Medical Research Hospital.

The study comprised 23 stomach cancer and 22 normal tissue samples. The Histo-RECAFTM test detected 82.6% of cancers with a specificity of 95.5%.

Dr. Taketa, a well known scientist in the area of cancer markers wrote in his letter to Dr. Moro: “Thank you for providing us the very valuable antibodies for RECAF. They can be used as the most specific and sensitive markers of malignancy”. Dr. Taketa added: ”We are in the process of writing a paper and submitting these results for publication in a peer reviewed journal”.

The letter, which can be read in the News section of our web site, also states that the results were accepted as a communication in the annual meeting of the International Society of Oncodevelopmental Biology and Medicine.

Dr. Moro stated: “I am extremely pleased with Dr. Taketa’s results and also because they were obtained completely independently from us, in their own laboratories and using their own funding.

Our investors should feel reassured by this independent validation of our technology. This report will hopefully put any questions about our claims to rest and help us in the process of licensing our technologies.

We expect that as more results come to light, more and more laboratories will take an interest on this remarkable molecule and participate in the work necessary to broaden the range of its applications.”

Dr. Phil Gold, Director and Chairman of BioCurex’s Scientific Advisory Board commented: “"The data obtain by Dr. Taketa`s group in Japan are most impressive. It is of interest that the results of the staining procedure are so close in both sensitivity and specificity to those previously obtained with the blood samples of cancer patients that have been studied. Obviously, more work is still required to allow for definitive conclusions, but this information is most exciting going forward."

The tissue results from Dr. Taketa’s group coincide with those obtained using BioCurex’s blood test -Serum-RECAF -as outlined in previous press releases which reported 84% detection of stomach cancers, and over 90% sensitivity (with 95% specificity) for breast, ovarian and lung cancers. This consistency is a critical feature of effective and valuable biotechnology.

A copy of Dr. Taketa’s letter will be placed on the website News section.

Each year, there are twenty-three thousand stomach cancers identified with 14,000 reported deaths in the USA alone. The incidence and mortality rates in China, the Koreas and Japan are 5-7 times higher. In Japan, stomach cancer is responsible for one out of four deaths by cancer. The high mortality rate is due to the late stages at which stomach cancer is detected. Early detection is the key to effective treatment.

About BioCurex:
Real-time Level II market quotes for BioCurex can be found at:

http://www.pinksheets.com/quote/quote.jsp?symbol=BOCX

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To read more about the Company, please visit the News section in our web site (www.biocurex.com).

Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are “forward-looking statements`` within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company`s actual results could differ materially from expected results.

Contact:
BioCurex, Inc
Tel: [phone]
www.biocurex.com

ich finde mit den News liegen die gut im Timing. die halten Ihre Aktionäre jedenfalls auf dem laufenden.
Gruß
Speku

[Preisfuchs]

na ist doch schön wenn man mit bocx zockt

[Spekulatius_28]

Die Post ist da

BioCurex On Its Way Back To The OTC:BB
Thursday July 22, 9:00 am ET


RICHMOND, British Columbia, July 22, 2004 (PRIMEZONE) -- BioCurex, Inc. (Other OTC:BOCX.PK - News) provides a Company update on its effort to reestablish trading on the NASD OTC:BB:
ADVERTISEMENT


Three months ago BioCurex underwent an investigation by the SEC. Following a sudden increase in the price of our stock, the Commission decided it was in the best interests of our investors to halt trading of BOCX shares for 10 days based on ``questions regarding the accuracy of assertions by BioCurex and others, in press releases and e-mails to investors concerning, among other things, (1) a study confirming the effectiveness of its primary product and (2) approval of its main product by the Food and Drug Administration``. The company immediately clarified any semantics in reference to the FDA classification of its Histo-RECAF technology and stood firmly by its reported results. Further, in an unprecedented move, a complete and detailed description of the raw scientific data including the statistical analysis of our lung cancer study was posted on the company web site for everyone to view.

Those same results, along with other studies, were subsequently presented in two congresses that gather international specialists in the field of cancer markers. The presentations elicited a significant amount of interest by very knowledgeable persons as outlined in a previous news release. It should be emphasized that we would not have gone to those congresses if we did not have complete confidence in our results, nor would those results have passed the scrutiny of the international scientific community in the field, if the results had not been well substantiated and valid -- which they were.

We have fully cooperated with the SEC, while standing by our claims, which are valid.

The trading suspension caused the company`s shares to be removed from the OTCBB. Since April 23rd 2004, our shares have traded in the ``Pink Sheets``, an unorganized market where actual Bid and Offer at any given time are not always available to all of our investors.

These events compounded with a delay in our financial reporting. Our Auditors insisted on a restatement of previous years` financial reports, although they had previously audited them to their satisfaction. That resulted in a considerable delay in filing our most recent 10K and 10Q, without which, we could not qualify for reinstatement in the NASD OTC:BB.

In the face of all these adversities, we feel that the company and its stock have performed well and Management wants to thank its staff and the professionals that helped us through these turbulent waters. We thank our shareholders for their faith in our ability to surmount this very difficult situation and for their faith in our technologies.

Our goal is to re-establish trading on the OTC:BB and we are now happy to announce that the company is again current in its audited statements and that a brokerage firm has already filed a Form 211c with the NASD, a necessary step to bring us back to the OTCBB. We anticipate the process to be completed in the upcoming weeks.

The outlook for BioCurex Inc. is exciting. As we move our business plan forward, we believe we will gain significant exposure for our technologies and awareness of our company in the industry. We look forward to a successful year.

To read more about the Company, please visit the News section in our web site (http://www.biocurex.com).

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (Other OTC:BOCX.PK - News), visit our website at http://www.biocurex.com.

Note:

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are ``forward-looking statements`` within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company`s actual results could differ materially from expected results.



Contact:
BioCurex, Inc.
Ricardo Moro
[phone]


--------------------------------------------------------------------------------
Source: BioCurex, Inc.

[Spekulatius_28]

BioCurex Reports Positive Results on Colon Cancer Using its RECAF Blood Test -- Assay is More Specific Than Currently Used Test
Wednesday September 8, 8:00 pm ET


RICHMOND, British Columbia, Sept. 8, 2004 (PRIMEZONE) -- BioCurex Inc. (Other OTC:BOCX.PK - News) is pleased to report positive detection results for an additional type of cancer using its RECAF(tm) based blood test.
ADVERTISEMENT


Seventy three samples from patients with colon cancer were compared to 352 normal samples. The RECAF based blood test detected 74% at 95% specificity and more importantly, the sensitivity remained over 71% when the specificity was increased to 100%(a).

The sensitivity of the RECAF(tm) assay is comparable to that of CEA, which is the current marker used for colon cancer diagnostic and follow-up, but the specificity of CEA is only 70-80%, which means that 20-30% of cancer free patients appear as false positives. This large number of false positives precludes the use of CEA for general screening. On the other hand, RECAF shows high sensitivity and high specificity, which makes it ideal for screening. This is important medically as well as commercially, since it can then be used on a much larger population than a marker used only for diagnosis and follow-up. The current market size for CEA and related markers is estimated to be approximately $300 million per year.

The results obtained on colon cancer are consistent with the results obtained in stomach, breast, lung and ovarian cancers using BioCurex`s patented RECAF technology. The ability to detect many different types of cancer with a single blood test is important economically and scientifically. The potential for widespread use of RECAF for cancer detection is enhanced and the potential for therapeutic use is increased. The finding of RECAF in many tissue types is somewhat unique and potentially points to a basic feature of cancer growth.

Dr. Moro stated: ``These results are not unexpected in view of the excellent figures we have obtained for other types of cancer. Colorectal cancer accounts for 12% of all cancers and despite the fact that it is the second cause of death by cancer (after lung cancer), it is highly curable if caught on time. Our next step is to determine how early we can detect this type of malignancy. An encouraging idea emerging from our study suggests that combining RECAF(tm) with CEA could greatly increase the overall sensitivity and specificity and that could translate into a much earlier diagnosis than what we have now. We are carrying on with our studies to further define the application.``

Dr. Moro added that the Company continues working towards reestablishing trading of its securities in the OTCBB.

About colon cancer:

Colorectal Cancer is the second most deadly form of cancer among men and women, second only to lung cancer. 130,000 Americans will be diagnosed this year with colorectal cancer and 56,000 will die from the disease. Worldwide the numbers for 2000 were 944,717 new cases and 510,021 deaths. If detected early, colorectal cancer is highly treatable and need not become deadly.

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (Other OTC:BOCX.PK - News), visit our website at http://www.biocurex.com.

Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are ``forward-looking statements`` within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company`s actual results could differ materially from expected results.

(a) Sensitivity is the number of true cancers picked by the test. Specificity is the percentage of normal samples that are negative with the test. A 95% specificity value is generally accepted as high for a cancer marker. The sensitivity and specificity of any test are a function of the cutoff value selected to discriminate normal from abnormal. Increasing that threshold leaves more normal samples below and therefore it improves the specificity, at the expense of the sensitivity.